Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Muhammad Usman, Tariq Jamal Siddiqi, Stefan D. Anker, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 25, pp. 2377-2387
Closed Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Empagliflozin after Acute Myocardial Infarction
Javed Butler, W. Schuyler Jones, Jacob A. Udell, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 16, pp. 1455-1466
Closed Access | Times Cited: 122
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis
Siddharth Patel, Yu Mi Kang, KyungAh Im, et al.
Circulation (2024) Vol. 149, Iss. 23, pp. 1789-1801
Open Access | Times Cited: 45
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
Adrian F. Hernandez, Jacob A. Udell, W. Schuyler Jones, et al.
Circulation (2024) Vol. 149, Iss. 21, pp. 1627-1638
Open Access | Times Cited: 28
Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis
Muhammad Usman, Deepak L. Bhatt, Ishaque Hameed, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 7, pp. 447-461
Closed Access | Times Cited: 27
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
Jacob A. Udell, Mark C. Petrie, W. Schuyler Jones, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 23, pp. 2233-2246
Open Access | Times Cited: 17
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy
Daniel P. Judge, Kevin Alexander, Francesco Cappelli, et al.
Journal of the American College of Cardiology (2025) Vol. 85, Iss. 10, pp. 1003-1014
Open Access | Times Cited: 2
Neurohumoral Activation in Heart Failure
Antonis A. Manolis, Theodora A. Manolis, Antonis S. Manolis
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15472-15472
Open Access | Times Cited: 32
The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure
Panagiotis Stachteas, Athina Nasoufidou, Dimitrios Patoulias, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3122-3122
Open Access | Times Cited: 14
Outcomes in Atrial Fibrillation Patients with Different Clinical Phenotypes: Insights from the French Population
Ameenathul M. Fawzy, Arnaud Bisson, Lisa Lochon, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1044-1044
Open Access | Times Cited: 1
Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis
Tayyab Shah, Zhiyuan Zhang, Hetakshi Shah, et al.
КАРДИОЛОГИЯ УЗБЕКИСТАНА (2025)
Closed Access | Times Cited: 1
Impact of Multimorbidity on Mortality in Heart Failure With Mildly Reduced and Preserved Ejection Fraction
Mingming Yang, Toru Kondo, Pooja Dewan, et al.
Circulation Heart Failure (2025)
Closed Access | Times Cited: 1
Impact of SGLT2 inhibitors on survival in gastrointestinal cancer patients undergoing chemotherapy and/or radiotherapy: a real-world data retrospective cohort study
Lucas E. Flausino, Alexis Germán Murillo Carrasco, Tatiane Katsue Furuya, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Takeshi Kitai, Shun Kohsaka, Takao Kato, et al.
Journal of Cardiac Failure (2025)
Closed Access | Times Cited: 1
Impact of Sodium‐Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity‐Score Matching Study and Meta‐Analysis
Zixu Zhao, Chao Jiang, Liu He, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 24
Open Access | Times Cited: 19
Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity
Vincenzo Quagliariello, Maria Laura Canale, Isabella Bisceglia, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 8
Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy
Vikash Jaiswal, Muhammad Hanif, Yusra Mashkoor, et al.
JACC Advances (2024) Vol. 3, Iss. 12, pp. 101405-101405
Open Access | Times Cited: 8
Renal upregulation of NCC counteracts empagliflozin-mediated NHE3 inhibition in normotensive but not in hypertensive male rat
Paulo C. Castro, Thiago M. Santos-Rios, Flavia L. Martins, et al.
AJP Cell Physiology (2024) Vol. 326, Iss. 6, pp. C1573-C1589
Closed Access | Times Cited: 6
Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose Cotransporter 2 Inhibitors: A systematic review
Rosalinda Madonna, Filippo Biondi, Mattia Alberti, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116650-116650
Open Access | Times Cited: 5
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
Claire L. Vale, Peter J. Godolphin, David J. Fisher, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 10, pp. 735-747
Open Access | Times Cited: 5
Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials
D Gomes, J Presume, Pedro de Araújo Gonçalves, et al.
Cardiovascular Drugs and Therapy (2024)
Closed Access | Times Cited: 4
Use of bailing capsules (cordyceps sinensis) in the treatment of chronic kidney disease: a meta-analysis and network pharmacology
Yilin Tao, Ruixiang Luo, Yuanbing Xiang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Impact of SGLT2 Inhibitors on Survival in Gastrointestinal Cancer Patients Undergoing Chemotherapy and/or Radiotherapy: A Real-World Data Retrospective Cohort Study
Lucas E. Flausino, Alexis Germán Murillo Carrasco, Tatiane Katsue Furuya, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Sodium–Glucose Cotransporter 2 Inhibitors as Potential Antioxidant Therapeutic Agents in Cardiovascular and Renal Diseases
Tapan Patel, Hong Zheng, Kaushik P. Patel
Antioxidants (2025) Vol. 14, Iss. 3, pp. 336-336
Open Access
Adoption and Prescribing Practices of Sodium-Glucose Transport Protein-2 (SGLT-2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Agonists in Cardiology: A Cross-Sectional Study in Saudi Arabia
Fatema Jamsheer, Anas AlAhmed, Noor H Alshamlan, et al.
Cureus (2025)
Open Access
SGLT2 inhibitor dapagliflozin mitigates skeletal muscle pathology by modulating key proteins involved in glucose and ion homeostasis in an animal model of heart failure
Elena Conte, Paola Imbrici, Giorgia Dinoi, et al.
European Journal of Pharmacology (2025), pp. 177617-177617
Open Access
Page 1 - Next Page

Scroll to top